TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
Los Alamos National Laboratory has developed the Clathrate Therapeutics Platform, a proprietary technology designed to overcome the longstanding challenges of delivering therapeutic gases safely and effectively by enabling localized, sustained release at the site of disease. This platform stabilizes gases within a biocompatible structure that releases them gradually under physiological conditions, minimizing systemic exposure and enhancing therapeutic precision. By targeting concentrations specifically to affected tissues, it improves the safety margin and expands the clinical potential of gas-based treatments in high-value areas such as oncology, cardiovascular disease, neurology, and regenerative medicine. Complementing the physical delivery system is an integrated predictive modeling capability that accelerates development by optimizing dosing parameters and treatment design before in vivo testing, reducing technical risk and streamlining translation to clinical applications. The technology is positioned as a versatile, platform-based solution that can be integrated with existing drug-device combinations and therapeutic modalities, making it suitable for partnerships across biotech, specialty pharma, and medical device industries. With a current technology readiness level of 2 and a U.S. patent pending under LA-UR-26-22810, it is in the early stages of development but represents a significant advancement in addressing delivery limitations that have hindered the clinical adoption of therapeutic gases. Licensing opportunities are available through exclusive or non-exclusive agreements managed by Los Alamos National Laboratory’s technology transfer program, with interested parties encouraged to engage via the provided contact information ahead of the December 2026 response deadline. The platform’s architecture and computational support make it uniquely suited to unlock new product categories and improve the viability of gas therapies in markets where efficacy has been demonstrated but delivery has been the barrier.
General Info
Agency
NAICS
Place of Performance
Los Alamos, NM, 87545, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Response Deadline
Organization & Contact Information
Full Description
This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value markets such as oncology, cardiovascular care, and regenerative medicine. In addition, the inclusion of a complementary predictive modeling capability supports treatment optimization and development efficiency, reducing technical risk and accelerating translation. Together, these capabilities position the technology as a differentiated and scalable solution that can unlock new commercial opportunities in areas where gas-based therapeutics have shown promise but faced delivery limitations.
The Opportunity:
Therapeutic gases have demonstrated meaningful biological effects across oncology, cardiovascular disease, neuroprotection and regenerative medicine, yet their clinical adoption has been limited by a fundamental challenge: safe, controlled and localized delivery. Existing approaches often result in rapid release, systemic exposure or narrow therapeutic windows, creating safety, regulatory and development barriers. The Clathrate Therapeutics Platform addresses this unmet need by positioning gas-based therapies as programmable, targetable and commercially viable treatment modalities. By enabling more precise control over where and how therapeutic gases are delivered, the platform has the potential to unlock new product categories, enhance combination treatment strategies and accelerate translation of gas-based therapeutics into high-value clinical markets.
How it Works:
The Clathrate Therapeutics Platform uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site rather than allowing them to disperse systemically. This technology temporarily stabilizes the gas within a biocompatible structure that gradually releases it under physiological conditions, enabling sustained and targeted exposure. This controlled release approach is designed to support therapeutic concentrations where needed while limiting circulating levels elsewhere in the body. An integrated computational modeling capability further supports optimization of dosing profiles and treatment parameters, helping guide development decisions prior to in vivo studies.
Key Advantages:
- Localized delivery: Targets therapeutic gases to the intended site while minimizing systemic exposure.
- Controlled release: Designed for sustained, tunable dosing under physiological conditions.
- Improved safety margin: Aims to separate therapeutic effect from toxicity risk.
- Platform versatility: Applicable across oncology, cardiovascular, neurological and regenerative indications.
- Development optimization: Supported by predictive modeling to guide dose and design decisions.
- Partnership-ready architecture: Suitable for integration with drug-device combinations and existing treatment modalities.
Market Applications:
- Oncology Therapeutics Industry
- Cardiovascular and Vascular Medicine Industry
- Neurology and Neurodegenerative Disease Sector
- Regenerative Medicine and Tissue Engineering Industry
- Medical Device and Drug-Device Combination Companies
- Biotechnology and Specialty Pharma Companies
- Computational Drug Development and Modeling Firms
Development Status: TRL 2
US patent pending
LA-UR-26-22810
LANL Tech Partnerships: Unlock the Innovative Potential
Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.
LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact licensing@lanl.gov.
Note: This is not a call for external services for the development of this technology.
https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology
m.lanl.gov/tech-search
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Energy → Triad - DOE Contractor
Same awarding agency
Ready to Pursue This Opportunity?
Get AI-powered intelligence on this solicitation and the ones like it
Every page of the solicitation package shredded into a compliance breakdown
AI-powered matching based on your capabilities and past performance
Competitor and incumbent history on the requirement
Automated alerts on amendments, Q&A deadlines, and award
Join 650+ contractors already using CLEATUS